UCB sets sights on rare diseases giant Alexion with Ra Pharm...

UCB is to buy US biotech Ra Pharma in a deal worth around $2.1 billion, adding a late-stage treatment for the rare muscle weakness disease myasthenia gravis to its R&D pipeline and sett

Roche preps filings for satralizumab in rare disease NMOSD

Alexion’s biosimilar-blocking EU patent play for Soliris fai...

Alexion's Soliris approved in new optic nerve disease use in...

Alexion’s rare disease drug Soliris has been approved in a new use in Europe, to tackle a disorder of the optic nerves for which it recently got FDA approval.

Alexion’s Soliris follow-up Ultomiris snares EU approval

R&D Roundup: Pharma gets in on the biotech boom

Some good news for the UK industry in turbulent times is always welcome, and several announcement this month showed us why the biotech sector in the country is looking extremely promising g